Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress

2024.01.03
Dr. Lai Wei talk about the Renaming of NAFLD to MASLD, Exploration of the Hepatitis B Research Paradigm, and Highlights from the 2023 EASL Congress Dr. Lai Wei is a Professor of Hepatology & Medicine, and is the Director of the Hepatobiliary and Pancreatic Center at Beijing Tsinghua Changgung Hospital. His current research interests involve antiviral treatment of hepatitis B and C. Dr. Wei is the President of the Chinese Society of Hepatology. He served to develop the Chinese Guideline for Management of Hepatitis B, and Management, Diagnosis and Prevention of Hepatitis C virus Infection. In addition, Dr Wei is involved in Kidney Disease Improving Global Outcome to develop a Guideline for HCV Infection, Diagnosis, Prevention and Management in Kidney Disease and contributes to APASL for hepatitis C guideline.
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

2024.01.03
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu University conducted research on the impact of NAFLD, as confirmed by liver histopathology, and pathological changes on individuals with chronic HBV infection. The latest research findings were selected for presentation at the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023
Dr. Yanhua Ding’s Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation

Dr. Yanhua Ding’s Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation

2024.01.02
Dr. Yanhua Ding's Team: Clinical Research on HBV CAM New Drugs and NAFLD Prediction Model Selected for Conference Presentation Yanhua Ding practices in Changchun, China. Ding and is rated as an Experienced expert by MediFind in the treatment of Arthritis. They are also highly rated in 3 other conditions, according to our data. Their top areas of expertise are Hepatitis, Hepatitis B, Hepatitis C, and Type 2 Diabetes (T2D).
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies

Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies

2024.01.02
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies Tarik Asselah is a Full Professor of Medicine and Hepatology at Hôpital Beaujon, APHP, Clichy, France, and at the University of Paris, France. Tarik Asselah is the Head of Viral Hepatitis at INSERM (UMR 1149, Centre de Recherche sur l’Inflammation). He is MD and also holds a PhD in virology. His fields of research include chronic liver diseases, translational medicine and treatment of HBV, HCV and HDV infections with new direct-acting antivirals, for which he has been involved as a coordinator/principal investigator in several clinical trials. He coordinated major international clinical trials on HCV, HBV and HDV infections. He has published more than 250 articles in the field of chronic liver diseases in major journals (NEJM, Lancet, Gastroenterology, Hepatology, Journal of Hepatology, etc…). (H-index = 60). He has been selected as a rising star in Gastroenteology in 2009 by the United European Gastroenterology (UEG) in appreciation of his outstanding scientific work. He received awards for his genomic studies on HCV in 2005 from the French Association for the Liver Disease (AFEF), and for his leadership in Hepatology in 2019 from the Czech Hepatology Society.
Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress

Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress

2024.01.02
Doctor Tom Hemming Karlsen Explains the EASL- The Lancet Liver Commission Initiative to Improve European Liver Health and Its Implementation Progress Tom Hemming Karlsen (MD, PhD) is a clinical specialist in internal medicine and gastroenterology working in Oslo, Norway. Dr. Karlsen graduated from medical school at the University of Bergen in 1997. In 2012 he was appointed professor of gastroenterology at the University of Bergen and in 2014 he was appointed full professor of internal medicine at the University of Oslo. Within the Oslo University Hospital he is Research Head of the Division of Surgery, Inflammatory medicine and Transplantation, and is also leader of the Norwegian PSC research center at the Department of Transplantation Medicine and Research Institute of Internal Medicine. Clinically, he works as a senior consultant within transplant hepatology at the Section of Gastroenterology at the Department of Transplantation Medicine